Alkem Laboratories Ltd. (ALKEM) fundamentals
Alkem Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ALKEM (ISIN INE540L01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Alkem Laboratories Ltd. does
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Valuation and market data
| Last close | ₹5138.00 |
|---|---|
| Market capitalisation | ₹62,804 crore |
| Enterprise value | ₹64,887 crore |
| P/E (TTM) | 26.69 |
| Price to book | 4.38 |
| Price to sales (TTM) | 2.36 |
| Book value per share | ₹1173.89 |
| Dividend yield | 103.15% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Dec 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹10,219 crore | ₹2,523 crore | ₹2,185 crore | 190.87 |
| Mar 2025 | ₹9,321 crore | ₹2,304 crore | ₹2,090 crore | 190.77 |
| Mar 2024 | ₹8,270 crore | ₹1,594 crore | ₹1,561 crore | 146.13 |
| Mar 2023 | ₹9,321 crore | ₹1,327 crore | ₹1,134 crore | 94.88 |
| Mar 2022 | ₹9,030 crore | ₹1,753 crore | ₹1,541 crore | 128.90 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 49.7% |
|---|---|
| Foreign institutions (FII) | 10.4% |
| Mutual funds | 16.7% |
| Other domestic institutions | 5.9% |
| Retail and others | 17.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.